clinical trial · NCT06238583
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
Bayer·—·no longer available
CancerCopanlisib (Aliqopa, BAY80-6946)
brief summary
The purpose of this Expanded Access Program (EAP) is to allow patients to continue receiving treatment with copanlisib if they are currently having, in the opinion of their healthcare provider, an objective favorable response when taking copanlisib. Patients considering this access program should have no other therapeutic option, have not developed a disease and/or medical condition (including pregnancy), and/or have a toxicity that would conflict with continuing to receive copanlisib.
started
—
primary completion
—
completion
—
last updated
Feb 2, 2024
official title
Copanlisib Expanded Access Program (EAP) for Patients Who, in the Opinion of Their Healthcare Provider, Are Deriving Benefit From Copanlisib Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol